PT85073A - Method for augmenting b-cell proliferation by means of ligands - Google Patents

Method for augmenting b-cell proliferation by means of ligands

Info

Publication number
PT85073A
PT85073A PT85073A PT8507387A PT85073A PT 85073 A PT85073 A PT 85073A PT 85073 A PT85073 A PT 85073A PT 8507387 A PT8507387 A PT 8507387A PT 85073 A PT85073 A PT 85073A
Authority
PT
Portugal
Prior art keywords
augmenting
ligands
cell proliferation
proliferation
cell
Prior art date
Application number
PT85073A
Other languages
Portuguese (pt)
Other versions
PT85073B (en
Inventor
Jeffrey A Ledbetter
Edward A Clark
Original Assignee
Oncogen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncogen filed Critical Oncogen
Publication of PT85073A publication Critical patent/PT85073A/en
Publication of PT85073B publication Critical patent/PT85073B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06Animal cells or tissues; Human cells or tissues
    • C12N5/0602Vertebrate cells
    • C12N5/0634Cells from the blood or the immune system
    • C12N5/0635B lymphocytes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT85073A 1986-06-13 1987-06-12 PROCESS FOR INCREASING PROLIFERATION OF B CELLS BY USING LIGANDS PT85073B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87388486A 1986-06-13 1986-06-13

Publications (2)

Publication Number Publication Date
PT85073A true PT85073A (en) 1987-07-01
PT85073B PT85073B (en) 1990-07-31

Family

ID=25362524

Family Applications (1)

Application Number Title Priority Date Filing Date
PT85073A PT85073B (en) 1986-06-13 1987-06-12 PROCESS FOR INCREASING PROLIFERATION OF B CELLS BY USING LIGANDS

Country Status (22)

Country Link
JP (1) JPH0762040B2 (en)
KR (1) KR910004100B1 (en)
AT (1) AT398437B (en)
AU (1) AU617087B2 (en)
BE (1) BE1000587A4 (en)
CA (1) CA1338781C (en)
CH (1) CH676600A5 (en)
CY (1) CY1681A (en)
DE (1) DE3719398C2 (en)
DK (1) DK173940B1 (en)
FR (1) FR2607136B1 (en)
GB (1) GB2191494B (en)
GR (1) GR870930B (en)
HK (1) HK10293A (en)
IE (1) IE60486B1 (en)
IL (1) IL82841A (en)
IT (1) IT1208649B (en)
LU (1) LU86919A1 (en)
NL (1) NL195022C (en)
PT (1) PT85073B (en)
SE (1) SE504675C2 (en)
SG (1) SG118992G (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506126A (en) * 1988-02-25 1996-04-09 The General Hospital Corporation Rapid immunoselection cloning method
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
RS50101B (en) * 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Pharmaceutical compositions for immunomodulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4443427A (en) * 1982-06-21 1984-04-17 Sidney Farber Cancer Institute, Inc. Monoclonal antibody
EP0117705A3 (en) * 1983-02-24 1985-09-25 The Regents Of The University Of California Monoclonal antibody specific for monocytes and blast cells
FR2547731A1 (en) * 1983-06-27 1984-12-28 Centre Nat Rech Scient ANTITUMOR IMMUNOTOXIN, PHARMACEUTICAL PREPARATIONS CONTAINING IT AND ITS USE IN VITRO
US4585742A (en) * 1983-12-14 1986-04-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibody with specificity to human small cell carcinoma and use thereof

Also Published As

Publication number Publication date
LU86919A1 (en) 1989-03-08
JPS6480299A (en) 1989-03-27
JPH0762040B2 (en) 1995-07-05
AT398437B (en) 1994-12-27
KR910004100B1 (en) 1991-06-22
DK302287A (en) 1987-12-14
BE1000587A4 (en) 1989-02-14
FR2607136A1 (en) 1988-05-27
AU7421487A (en) 1987-12-17
IE871563L (en) 1987-12-13
FR2607136B1 (en) 1989-09-15
DE3719398C2 (en) 1996-03-28
SG118992G (en) 1993-01-29
PT85073B (en) 1990-07-31
NL8701371A (en) 1988-01-04
DE3719398A1 (en) 1988-01-28
GR870930B (en) 1987-12-16
IT8720899A0 (en) 1987-06-12
IT1208649B (en) 1989-07-10
NL195022C (en) 2003-06-18
DK173940B1 (en) 2002-03-04
ATA151387A (en) 1994-04-15
GB2191494A (en) 1987-12-16
IL82841A (en) 1992-11-15
GB8713650D0 (en) 1987-07-15
SE504675C2 (en) 1997-04-07
SE8702463L (en) 1987-12-14
IE60486B1 (en) 1994-07-27
HK10293A (en) 1993-02-19
CY1681A (en) 1993-10-10
DK302287D0 (en) 1987-06-12
AU617087B2 (en) 1991-11-21
GB2191494B (en) 1990-08-22
CH676600A5 (en) 1991-02-15
IL82841A0 (en) 1987-12-20
KR880000582A (en) 1988-03-28
SE8702463D0 (en) 1987-06-12
CA1338781C (en) 1996-12-10

Similar Documents

Publication Publication Date Title
BG46159A3 (en) Method for preparing of prteine, heterolog microorganism
BG48811A3 (en) Method for preparing of 2- bromine- alpha- ergokryptins
HUT38616A (en) Process for preparing octahydrobenzo/f/quinoline-derivatives
EP0254574A3 (en) Method for producing plzt powder
EG16472A (en) Method of preparing 3-phenoxy-1-azetidinecarboxamides
BG49383A3 (en) Method for preparing of thiopheni
GB2165671B (en) Timing method & apparatus
GB8805899D0 (en) Apparatus for controlling number of revolution of i c engine
PT85073A (en) Method for augmenting b-cell proliferation by means of ligands
BG50161A3 (en) Method for preparing of alcandiol dicarboxilates
DE3663661D1 (en) Process for synthesizing n-acetylglycine using novel promoters
BG49938A3 (en) Method for preparing of anilinefumarate
PT84666A (en) Improved method for synthesizing n-aminophthalimide
BG44377A3 (en) Method for preparing of condensnd as- triazines
BG44375A3 (en) Method for preparing of condensnd as- triazines
BG43458A1 (en) Method for preparing of anticandidosic means
BG45696A3 (en) Method for preparing of alylchloride
GR862100B (en) Method for preparing novel benzodioxepanne
GB2187179B (en) Method of preparing perfluorosilanes from perchlorosilanes
YU43154B (en) Process for preparing n-mono- and n,n-dissubstituted derivates of 4-methyl-5-oxazolo-carboxamides
BG43436A1 (en) Method for preparing of benzhydrylchloride
BG45915A1 (en) Method for preparing of n- benzoil n- phenyl- hydroxylamin
BG49961A1 (en) Method for preparing of material- catalyst carrier
BG47420A1 (en) Method for preparing of isocitratedehydrogenase
BG42762A1 (en) Method for preparing unsaturated polyaminoesteramides